Search

Search Results

1. The usefulness of [⁶⁸ Ga]Ga-DOTA-JR11 PET/CT in patients with meningioma: comparison with MRI

   Purpose

   Clinical studies of PET imaging using SSTR2 agonists have demonstrated high accuracy and correlation with SSTR2 expression in meningiomas....

   Peipei Wang, Shuai Liu, ... **n Cheng in European Journal of Nuclear Medicine and Molecular Imaging

   Article 08 September 2023
   

2. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [¹⁸F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [⁶⁸Ga]Ga-DOTA-TATE

   Purpose

   A [ ¹⁸ F]AlF-labeled somatostatin receptor (SSTR) antagonist was developed for imaging of neuroendocrine neoplasms (NENs), evaluated and...

   Qing **e, Teli Liu, ... Zhi Yang in European Journal of Nuclear Medicine and Molecular Imaging

   Article 25 February 2021
   

3. Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China

   Purpose

   Somatostatin receptor antagonists have shown promising performance for imaging neuroendocrine neoplasms. However, there is a lack of studies...

   Meixi Liu, Yuejuan Cheng, ... Li Huo in European Journal of Nuclear Medicine and Molecular Imaging

   Article 10 February 2024
   

4. Comparison of ⁶⁸Ga-DOTA-JR11 PET/CT with dosimetric ¹⁷⁷Lu-satoreotide tetraxetan (¹⁷⁷Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy

   Purpose

   Paired imaging/therapy with radiolabeled somatostatin receptor (SSTR) antagonists is a novel approach in neuroendocrine tumors (NETs). The aim...

   Simone Krebs, Joseph A. O’Donoghue, ... Neeta Pandit-Taskar in European Journal of Nuclear Medicine and Molecular Imaging

   Article 06 May 2020
   

5. Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification

   Purpose

   Many radioligands have been developed for the visualization of atherosclerosis by targeting inflammation. However, interpretation of in vivo...

   Eric J. Meester, Erik de Blois, ... Kim van der Heiden in EJNMMI Research

   Article Open access 17 March 2021
   

6. Theranostics with Somatostatin Receptor Antagonists

   Somatostatin receptors (SST), especially SST subtype 2 (SST2), are important targets for the management of patients with neuroendocrine tumours...

   Damian Wild in Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum

   Chapter Open access 2024
   

7. Case Study #6: [177Lu]Lu-DOTA-JR11: A Somatostatin Receptor Subtype 2 Antagonist for Radiopharmaceutical Therapy

   Peptide receptor radionuclide therapy (PRRT) is a special type of radiopharmaceutical therapy (RPT) that employs peptide-based radiopharmaceuticals...

   Damian Wild, Melpomeni Fani in Radiopharmaceutical Therapy

   Chapter 2023
   

8. Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update

   Purpose of Review

   This paper aims to address the latest findings in neuroendocrine tumor (NET) theranostics, focusing on new evidence and future...

   Martina Di Franco, Lucia Zanoni, ... Valentina Ambrosini in Current Oncology Reports

   Article Open access 06 April 2024
   

9. Theranostics in Neuroendocrine Tumors

   Neuroendocrine neoplasms (NENs) are a heterogeneous group of epithelial neoplastic proliferations ranging from indolent well differentiated...

   Shankar Vallabhajosula in Molecular Imaging and Targeted Therapy

   Chapter 2023
   

10. Theranostic Imaging and Radiopharmaceutical Therapy

    The over-arching concept of “theranostics” has been described by various groups (Bodei et al., Nat Rev Clin Oncol 19:534–550, 2022, Baum and...

    Heying Duan, Andrei Iagaru in Radiopharmaceutical Therapy

    Chapter 2023
    

11. Highlight selection of radiochemistry and radiopharmacy developments by editorial board

    Background

    The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in...

    Jean DaSilva, Clemens Decristoforo, ... Sarah Spreckelmeyer in EJNMMI Radiopharmacy and Chemistry

    Article Open access 27 October 2023
    

12. Evaluation of the safety, biodistribution, dosimetry of [¹⁸F]AlF-NOTA-LM3 and head-to-head comparison with [⁶⁸Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial

    Purpose

    ¹⁸ F-labelled somatostatin receptor (SSTR) analogs offer several advantages over ⁶⁸ Ga in terms of yield, cost, spatial resolution and...

    Meixi Liu, Chao Ren, ... Li Huo in European Journal of Nuclear Medicine and Molecular Imaging

    Article 15 June 2024
    

13. Design of Radiolabeled Peptide Radiopharmaceuticals

    Peptides are short chains of amino acids (AA) containing less than 40–50 AAs. Twenty AAs appear in the genetic code and are considered as “standard”...

    Shankar Vallabhajosula in Molecular Imaging and Targeted Therapy

    Chapter 2023
    

14. New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms

    Neuroendocrine neoplasms (NEN) are a heterogeneous group of tumours derived from cells of neuroendocrine origin and can potentially arise everywhere...

    Emilia Fortunati, Giulia Argalia, ... Valentina Ambrosini in Current Treatment Options in Oncology

    Article Open access 24 March 2022

15. Molecular Imaging Platform and Radiopharmaceutical Translational Research on Peking University Cancer Hospital

    On August 27, 2019, the signing ceremony for the cooperation between Peking University Cancer Hospital (PKUCH) and the International Centers for...

    Zhi Yang, **angxi Meng, ... Hua Zhu in Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum

    Chapter Open access 2024
    

16. Perspektiven der PET-Radiopharmaka und Bildgebung: Von FDG bis FAPi, vom PETScanner zum digitalen Ganzkörpertool

    Die Komplexität der PET/CT, welche sich sowohl aus den gerätetechnischen Parametern eines Hybridverfahrens, aber auch aus den zum Einsatz kommenden...

    Wolfgang Mohnike, Konrad Mohnike, ... Sarah Hildebrandt in PET/CT-Atlas

    Chapter 2024
    

17. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of ⁶⁸Ga-NODAGA-LM3 and ⁶⁸Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with ⁶⁸Ga-DOTATATE

    Purpose

    The purpose of this study is to evaluate the diagnostic efficacy of ⁶⁸  Ga-NODAGA-LM3 and ⁶⁸  Ga-DOTA-LM3 and compare them with ⁶⁸ Ga-DOTATATE...

    Wenjia Zhu, Ru Jia, ... Li Huo in European Journal of Nuclear Medicine and Molecular Imaging

    Article 07 December 2021
    

18. Biodistribution and radiation dose estimates for ⁶⁸Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors

    Purpose

    Somatostatin receptor antagonists have shown promise for imaging neuroendocrine tumors (NETs) in preclinical studies, but clinical data is...

    Simone Krebs, Neeta Pandit-Taskar, ... Joseph A. O’Donoghue in European Journal of Nuclear Medicine and Molecular Imaging

    Article 29 October 2018
    

19. Peptides as Vectors for Radiopharmaceutical Therapy

    Radiolabeled receptor-binding peptides enable the selective delivery of radionuclides to target tissues (e.g., tumor) while reducing radiation...

    Ryan A. Davis, Tanushree Ganguly, ... Julie L. Sutcliffe in Radiopharmaceutical Therapy

    Chapter 2023
    

20. Molecular Imaging in Oncology

    Radioisotope-based molecular imaging (MI) techniques such as PET/CT and SPECT/CT aim to integrate patient-specific and disease-specific molecular...

    Shankar Vallabhajosula in Molecular Imaging and Targeted Therapy

    Chapter 2023